Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/205802
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rosiñol, Laura | - |
dc.contributor.author | Hebraud, Benjamin | - |
dc.contributor.author | Oriol, Albert | - |
dc.contributor.author | Colin, Anne Laurène | - |
dc.contributor.author | Ríos Tamayo, Rafael | - |
dc.contributor.author | Hulin, Cyrille | - |
dc.contributor.author | Blanchard, María Jesús | - |
dc.contributor.author | Caillot, Denis | - |
dc.contributor.author | Sureda, Anna | - |
dc.contributor.author | Hernández, Miguel Teodoro | - |
dc.contributor.author | Arnulf, Bertrand | - |
dc.contributor.author | Mateos, Maria Victoria | - |
dc.contributor.author | Macro, Margaret | - |
dc.contributor.author | San Miguel, Jesús | - |
dc.contributor.author | Belhadj, Karim | - |
dc.contributor.author | Lahuerta, Juan José | - |
dc.contributor.author | Garelik, M. Brigid | - |
dc.contributor.author | Bladé, Joan | - |
dc.contributor.author | Moreau, Philippe | - |
dc.date.accessioned | 2024-01-16T22:20:28Z | - |
dc.date.available | 2024-01-16T22:20:28Z | - |
dc.date.issued | 2023-11-02 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | http://hdl.handle.net/2445/205802 | - |
dc.description.abstract | ObjectiveProviding the most efficacious frontline treatment for newly diagnosed multiple myeloma (NDMM) is critical for patient outcomes. No direct comparisons have been made between bortezomib + lenalidomide + dexamethasone (VRD) and bortezomib + thalidomide + dexamethasone (VTD) induction regimens in transplant-eligible NDMM.MethodsAn integrated analysis was performed using patient data from four trials meeting prespecified eligibility criteria: two using VRD (PETHEMA GEM2012 and IFM 2009) and two using VTD (PETHEMA GEM2005 and IFM 2013-04).ResultsThe primary endpoint was met, with VRD demonstrating a noninferior rate of at least very good partial response (>= VGPR) after induction vs VTD. GEM comparison demonstrated improvement in the >= VGPR rate after induction for VRD vs VTD (66.3% vs 51.2%; P = .00281) that increased after transplant (74.4% vs 53.5%). Undetectable minimal residual disease rates post induction (46.7% vs 34.9%) and post transplant (62.4% vs 47.3%) support the benefit of VRD vs VTD. Treatment-emergent adverse events leading to study and/or treatment discontinuation were less frequent with VRD (3%, GEM2012; 6%, IFM 2009) vs VTD (11%, IFM 2013-04).ConclusionThese results supported the benefit of VRD over VTD for induction in transplant-eligible patients with NDMM. The trials included are registered with ClinicalTrials.gov (NCT01916252, NCT01191060, NCT00461747, and NCT01971658). | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media SA | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fonc.2023.1197340 | - |
dc.relation.ispartof | Frontiers in Oncology, 2023, vol. 13 | - |
dc.relation.uri | https://doi.org/10.3389/fonc.2023.1197340 | - |
dc.rights | cc by (c) Rosiñol, Laura et al., 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Mieloma múltiple | - |
dc.subject.classification | Terapèutica | - |
dc.subject.other | Multiple myeloma | - |
dc.subject.other | Therapeutics | - |
dc.title | Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-12-13T12:45:55Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 38023148 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fonc-13-1197340.pdf | 1.64 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License